HGL Private Capital is pleased to announce the successful exit from Futuremeds, a leading independent clinical trials business in Europe, to Phoenix Equity Partners. This strategic transaction marks an important milestone for Futuremeds, showcasing its growth and innovation in the clinical trials sector.
HGL Private Capital first invested in Futuremeds in 2021, recognising its potential in the rapidly evolving healthcare landscape. In 2023, HGL further reinforced its commitment by providing additional funding to support the company’s organic growth and its ambitious buy-and-build strategy. This investment enabled FutureMeds to expand its capabilities and strengthen its position in the European clinical trials market.
Under the exceptional leadership of Dr. Radoslaw Janiak, Marcin Gondek, and Paul Chambers, FutureMeds transformed into a market leader, delivering high-quality clinical trials solutions and outstanding services to its clients across Europe. Radoslaw and the management team have done a remarkable job building the business, exemplifying dedication and vision that have significantly contributed to its current success. FutureMeds has grown from 6 sites in 2021 to 28 locations spanning the UK, Poland, Germany, Spain, Bulgaria, Ukraine & Romania.
Paul Chambers, Chairman of Futuremeds, expressed his appreciation for HGL Private Capital’s involvement, stating, “HGL Private Capital has been a tremendous support for Futuremeds. Their commitment and strategic insights were invaluable in our journey to becoming the leading independent clinical trials business in Europe. We are grateful for their partnership and are excited to embark on this next chapter with Phoenix Equity Partners.”
Ged Gould of HGL Private Capital added, “It’s been a pleasure working with Radek and the entire management team at FutureMeds. They have done an outstanding job driving the company’s growth, and we are proud to have played a role in their success. We wish them all the best for the future as they continue to innovate and lead in the clinical trials industry.”
As FutureMeds embarks on this new journey with Phoenix Equity Partners, HGL Private Capital extends its best wishes for continued success and growth in the evolving landscape of clinical trials. HGL achieved a 10x money multiple on their initial investment from 2021.
